<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329589</url>
  </required_header>
  <id_info>
    <org_study_id>05C.255</org_study_id>
    <secondary_id>2005-28</secondary_id>
    <secondary_id>NCI-2009-01797</secondary_id>
    <nct_id>NCT00329589</nct_id>
  </id_info>
  <brief_title>A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients</brief_title>
  <official_title>A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of Velcade when used with chemoradiation
      in cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of
           Velcade® when administered as a twice weekly 3-5 second IV bolus every 3 weeks to
           patients with malignancies of the brain, head and neck and cervix who receive 2-8 weeks
           of chemoradiation.

        -  To evaluate the safety and toxicity profile of Velcade® when administered on a twice
           weekly (days 1, 4, 8 and 11) every 3 weeks (maximum 8 weeks) concurrent with
           chemoradiation.

        -  To evaluate tumor response
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safe and maximum tolerated dose of Velcade® when administered as a twice weekly 3-5 second intravenous (IV) bolus every 3 weeks to patients with malignancies of the brain, head and neck, and cervix who receive 2-8 weeks of radiotherapy</measure>
    <time_frame>2-8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Cervix Cancer</condition>
  <condition>Central Nervous System Neoplasms</condition>
  <arm_group>
    <arm_group_label>CNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velcade (bortezomib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and Neck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velcade (bortezomib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velcade (bortezomib)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade (bortezomib)</intervention_name>
    <arm_group_label>CNS</arm_group_label>
    <arm_group_label>Head and Neck</arm_group_label>
    <arm_group_label>Cervix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignancy

          -  Requiring at least grade 2 weeks of radiation therapy

          -  Solid tumors of the central nervous system, head and neck area, and cervix

          -  World Health Organization (WHO) performance status equal to or less than 2

        Exclusion Criteria:

          -  Equal to or greater than grade 2 peripheral neuropathy

          -  Myocardial infarction within 6 months

          -  Hypersensitivity to bortezomib, boron, or mannitol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Dicker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2006</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignancies of the central nervous system, head and neck area</keyword>
  <keyword>and cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

